Skip to main content
. 2015 Jun 15;8(6):10187–10203.

Table 3.

Meta-analysis results

t vs. T tt vs. TT tt vs. Tt + TT Tt vs. TT tt + Tt vs. TT
N OR (95% CI) Heterogeneity (I2, PQ) OR (95% CI) Heterogeneity (I2, PQ) OR (95% CI) Heterogeneity (I2, PQ) OR (95% CI) Heterogeneity (I2, PQ) OR (95% CI) Heterogeneity (I2,PQ)
Total 38 1.03 (0.97, 1.09)F 47.5%; 0.001 1.09 (0.96, 1.25)F 46.9%, 0.001 1.05 (0.92, 1.19)F 42.2%, 0.004 1.03 (0.96, 1.12)F 37%, 0.013 1.04 (0.96, 1.12)F 40.3%, 0.006
Ethnicities
    ES Asians 11 0.93 (0.77, 1.11)F 0%; 0.707 0.93 (0.55, 1.57)F 0%, 0.996 0.89 (0.53, 1.48)F 0%, 0.998 0.94 (0.76, 1.16)F 0%, 0.494 0.93 (0.76, 1.14)F 0%, 0.587
    SW Asians 15 1.27 (1.07, 1.51)* 63.0%; 0.001 1.59 (1.11, 2.26)* 56.5%, 0.004 1.43 (1.17, 1.73)*,F 46%, 0.026 1.25 (0.99, 1.59) 57.8%, 0.003 1.32 (1.05, 1.67)* 61.6%, 0.001
    Africans 8 0.95 (0.87, 1.03)F 0%; 0.432 0.86 (0.64, 1.16) 51.2%, 0.045 0.86 (0.64, 1.15) 51.9%, 0.042 0.98 (0.88, 1.10)F 0%, 0.927 0.96 (0.86, 1.07)F 0%, 0.884
    Americans 2 0.92 (0.43, 1.97) 67.9%; 0.078 1.69 (0.48, 5.96)F 0%, 0.488 1.56 (0.46, 5.33)F 0%, 0.559 0.91 (0.43, 1.91) 54.2%, 0.14 0.92 (0.40, 2.09) 63.7%, 0.097
    Europeans 2 0.94 (0.70, 1.27)F 0%; 0.894 0.32( 0.03,3.85) 66.2%, 0.086 0.20 (0.01, 6.66) 82.5%, 0.017 1.70 (0.61, 4.74) 79.9%, 0.026 1.39 (0.66, 2.95) 65.1%, 0.091
Sample size
    Largea 9 0.97 (0.89, 1.04)F 29.0%; 0.187 0.96 (0.70, 1.31) 61.7%, 0.008 0.98 (0.70, 1.37) 68.7%, 0.001 0.94 (0.85, 1.04)F 12.1%, 0.334 0.94 (0.85, 1.04)F 0%, 0.530
    Smallb 29 1.12 (1.03, 1.23)*,F 47.2%; 0.003 1.24 (1.02, 1.52)*,F 39.1%, 0.019 1.09 (0.91, 1.31)F 25.6%, 0.109 1.18 (1.05, 1.33)*,F 33.4%, 0.043 1.17 (1.05, 1.31)*,F 41%, 0.012
Genotyping method
    PCR-RFLP 29 1.10 (0.98, 1.23) 51.8%; 0.001 1.26 (1.08, 1.46)*,F 40.6%, 0.015 1.20 (1.04, 1.39)*,F 29.5%, 0.073 1.04 0.94, 1.14)F 37.3%, 0.024 1.06 (0.97, 1.16)F 45.1%, 0.005
    Other methods 9 0.92 (0.83, 1.03)F 0%; 0.594 0.73 (0.56, 0.95)*,F 19.4%, 0.27 0.69 (0.54, 0.90)*,F 45.6%, 0.065 1.03 (0.89, 1.19)F 42.8%, 0.082 0.97 (0.85, 1.12)F 19.4%, 0.270
Source of controls
    Contactsc 11 1.06 (0.93, 1.21)F 0.0%; 0.526 1.15 (0.83, 1.60)F 0%, 0.857 1.13 (0.82, 1.55)F 0%, 0.875 1.05 (0.88, 1.25)F 0%, 0.510 1.06 (0.90, 1.25)F 0%, 0.478
    Healthyd 27 1.06 (0.95, 1.18) 57.5%; 0.000 1.16 (0.89, 1.53) 58.8%, 0.000 1.07 (0.84, 1.38) 55%, 0.000 1.03 (0.94, 1.12)F 47.4%, 0.004 1.08 (0.94, 1.23) 50.2%, 0.002
HWE
    PHWE>0.05 29 1.05 (0.94, 1.17) 54.9%; 0.000 1.14 (0.87, 1.48) 53.9%, 0.000 0.97 (0.84, 1.12)F 43.3%, 0.008 1.05 (0.96, 1.15)F 34.9%, 0.034 1.04 (0.95, 1.13)F 45.1%, 0.005
    PHWE<0.05 9 1.09 (0.96, 1.23)F 0%; 0.476 1.35 (1.02, 1.78)*,F 0%, 0.569 1.33 (1.02, 1.73)*,F 27.3%, 0.201 0.97 (0.82, 1.16)F 47.2%, 0.056 1.03 (0.87, 1.21)F 27.5%, 0.200
Tuberculosis type
    pulmonary 29 1.05 (0.95, 1.17) 53.2%; 0.000 1.15 (0.90, 1.48) 52.6%, 0.001 1.03 (0.90, 1.18)F 48.5%, 0.002 1.03 (0.94, 1.12)F 46%, 0.003 1.02 (0.94, 1.11)F 47.9%, 0.002
    Extra and pulmonary 7 1.13 (0.95, 1.33)F 30%; 0.21 1.29 (0.84, 1.96)F 39.6%, 0.141 1.22 (0.81, 1.82)F 35.7%, 0.169 1.12 (0.90, 1.39)F 0%, 0.545 1.14 (0.93, 1.41)F 0.9%, 0.410
    extra 2 0.97 (0.70, 1.36)F 0%; 0.855 1.00 (0.49, 2.04)F 0%, 0.876 1.06 (0.55, 2.06)F 0%, 0.915 0.90 (0.55, 1.46)F 0%, 0.873 0.92 (0.58, 1.46)F 0%, 0.855

Abbreviations: N: number of studies included; OR: odds ratio; Ph: p value for heterogeneity; PQ: Cochran’s Q statistics; I2: Higgin’s I2 statistics.

F

Results derived using Fixed effects for analysis. Random effects were used for all other calculations.

*

OR with statistical significance;

a

studies with more than 500 participants;

b

studies with less than 5000 participants;

c

studies with controls from patient contacts;

d

studies with controls from healthy person.